Immunoblot assays revealed that CAPE treatment (20 μM) upregulated MT2A and HO-1 expressions in bladder carcinoma T24 cells; moreover, knockdown of MT2A attenuated the activation of CAPE on HO-1 protein levels (Figure 5A, left). Here, SMC2 is linked to urinary bladder carcinoma.